SCHEMBL6604015

SCHEMBL6604015

CCOc1cc(-c2ccccc2)nn1CCOc1ccc2cc(C#N)ccc2c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCEH1 Q6PIU2 1/20 0.40
ADORA1 P30542 2/20 0.37
EIF4EBP1 Q13541 5/20 0.37
ADORA2A P29274 2/20 0.35
ICMT O60725 1/20 0.33
PDE5A O76074 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PIN1 Q13526 1/20 0.32
CYP19A1 P11511 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
SQOR Q9Y6N5 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6601564 0.90 KDM4E (0.36) ADORA1EIF4EBP1ADORA2AICMTALDH1A1
SCHEMBL6805250 0.87 ICMT (0.42) EIF4EBP1ICMTPDE5ASMN1; SMN2LMNA
SCHEMBL6607058 0.86 ADORA1 (0.41) NCEH1ADORA1ADORA2AALDH1A1HTT
SCHEMBL6602524 0.77 ADORA1 (0.40) NCEH1ADORA1ADORA2AALDH1A1HTT
SCHEMBL6602658 0.76 HPGD (0.42) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL6604163 0.76 S1PR4 (0.40) ADORA1ALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL6606370 0.76 SCN9A (0.38) ADORA1EIF4EBP1ADORA2AALDH1A1SMN1; SMN2
SCHEMBL6604165 0.75 MAPT (0.46) ADORA1ADORA2AALDH1A1HTTSMN1; SMN2
SCHEMBL6805998 0.74 HPGD (0.41) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL6603514 0.74 NLRP3 (0.41) EIF4EBP1SMN1; SMN2LMNAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 NCEH1 3856/4885ADORA1 3424/4885EIF4EBP1 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.